{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.65","value":"0.12"},{"groupId":"OG001","spread":"0.92","value":"1.16"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"441"},{"groupId":"OG001","value":"223"}],"units":"Participants"}],"description":"European Quality of Life-5 Dimensions-5 Level (EQ-5D-5L) is a standardized measure of health status of the participant. The EQ-5D-5L is assessed using a visual analog scale (VAS) that ranged from 0 to 100mm, where 0 is the worst health you can imagine and 100 is the best health you can imagine. A higher score indicates better health state. LS Mean value was controlled for Treatment, visit, Treatment\\*Visit and baseline.","dispersionType":"Standard Error","groups":[{"description":"Abemaciclib 150 mg administered orally every 12 hours on Days 1 to 28 of a 28-day cycle in combination with fulvestrant 500mg administered IM on Days 1 and 15 of Cycle 1, then on Day 1 of Cycle 2 and beyond. Participants received treatment until discontinuation were met.","id":"OG000","title":"Abemaciclib + Fulvestrant"},{"description":"Placebo administered orally every 12 hours on Days 1 to 28 of a 28-day cycle in combination with fulvestrant 500mg administered IM on Days 1 and 15 of Cycle 1, then on Day 1 of Cycle 2 and beyond. Participants received treatment until discontinuation were met.","id":"OG001","title":"Placebo + Fulvestrant"}],"paramType":"LEAST_SQUARES_MEAN","populationDescription":"All randomized participants who received at least one dose of study drug with baseline and post-baseline EQ-5D 5L data.","reportingStatus":"POSTED","timeFrame":"Baseline, End of Study (Up To 31 Months)","title":"Change From Baseline in Health Status Using the EuroQol 5-Dimension 5 Level (EQ-5D 5L)","type":"SECONDARY","unitOfMeasure":"mm"}